Synonyms: AZD 4017 | AZD-4017
Compound class:
Synthetic organic
Comment: AZD4017 is a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) [2-3]. This compound is listed in AstraZeneca's OpenInnovation Pharmacology Toolbox .
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Eckel RH, Grundy SM, Zimmet PZ. (2005)
The metabolic syndrome. Lancet, 365 (9468): 1415-28. [PMID:15836891] |
2. McCoull W, Packer M, Scott JS , Whittamore PRO. (2009)
Chemical compounds. Patent number: US20090306075. Assignee: Astrazeneca Ab. Priority date: 03/11/2006. Publication date: 10/12/2009. |
3. Scott JS, Bowker SS, Deschoolmeester J, Gerhardt S, Hargreaves D, Kilgour E, Lloyd A, Mayers RM, McCoull W, Newcombe NJ et al.. (2012)
Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017). J Med Chem, 55 (12): 5951-64. [PMID:22691057] |
4. Stimson RH, Walker BR. (2007)
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Minerva Endocrinol, 32 (3): 141-59. [PMID:17912154] |
5. Walker BR. (2007)
Glucocorticoids and cardiovascular disease. Eur J Endocrinol, 157 (5): 545-59. [PMID:17984234] |